Blood cell changes in complement activation-related pseudoallergy

European Journal of Nanomedicine

Volumn 7, Issue 3, 2015, Pages 233-244

  Patkó, Zsófia ^a   Szebeni, János ^b,c  

^a Borsod County Teaching Hospital   (Hungary)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c UNIVERSITY OF MISKOLC   (Hungary)

Author keywords

anaphylatoxins; animal models; hypersensitivity reactions; platelets; pseudoallergy; white blood cells

Indexed keywords

ANIMALS; CELL MEMBRANES; CHEMICAL ACTIVATION; ENDOTHELIAL CELLS; MICROCIRCULATION; PLATELETS; SURFACE REACTIONS;

ANAPHYLATOXINS; ANIMAL MODEL; HYPERSENSITIVITY REACTION; PSEUDOALLERGY; WHITE BLOOD CELLS;

CYTOLOGY;

ANAPHYLATOXIN; ANTIHISTAMINIC AGENT; ANTIINFLAMMATORY AGENT; CELL SURFACE RECEPTOR; COMPLEMENT; COMPLEMENT COMPONENT C3B; PADGEM PROTEIN; STEROID;

ALLERGY; ANAPHYLAXIS; BLOOD CELL; CELL INTERACTION; COMPLEMENT ACTIVATION; COMPLEMENT ACTIVATION RELATED PSEUDOALLERGY; ENDOTHELIUM CELL; EXPERIMENTAL MODEL; HUMAN; LEUKOCYTE; LEUKOCYTE AGGREGATION; LEUKOCYTOSIS; LEUKOPENIA; MACROPHAGE; MIMOSA; MOLECULAR INTERACTION; MONOCYTE; NONHUMAN; PIG; PLATELET MICROPARTICLE; PULMONARY HYPERTENSION; REVIEW; SECRETORY CELL; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

EID: 84931052798     PISSN: 16625986     EISSN: 1662596X     Source Type: Journal    
DOI: 10.1515/ejnm-2015-0021     Document Type: Review

References (67)

1. Szebeni J. Complement activation-related pseudoallergy caused by liposomes, micellar carriers of intravenous drugs and radiocontrast agents. Crit Rev Ther Drug Carr Syst 2001;18:567-606.
2. Szebeni J. Complement activation-related pseudoallergy: mechanism of anaphylactoid reactions to drug carriers and radiocontrast agents. In: Szebeni J, editor. The complement system: novel roles in health and disease. Boston: Kluwer, 2004:399-440.
3. Szebeni J. Complement activation-related pseudoallergy: a new class of drug-induced immune toxicity. Toxicology 2005;216:106-21.
4. Szebeni J, Alving CR, Rosivall L, Bünger R, Baranyi L, Bedöcs P, et al. Animal models of complement-mediated hypersensitivity reactions to liposomes and other lipid-based nanoparticles. J Liposome Res 2007;17:107-17.
5. Szebeni J, Muggia F, Gabizon G, Barenholz Y. Activation of complement by therapeutic liposomes and other lipid excipientbased therapeutic products: prediction and prevention. Adv Drug Deliv Rev 2011;63:1020-30.
6. Szebeni J. Hemocompatibility testing for nanomedicines and biologicals: predictive assays for complement mediated infusion reactions. Eur J Nanomed 2012;5:33-53.
7. Szebeni J, Bedocs P, Csukas D, Rosivall L, Bunger R, Urbanics R. A porcine model of complement-mediated infusion reactions to drug carrier nanosystems and other medicines. Adv Drug Deliv Rev 2012;64:1706-16.
8. Szebeni J. Complement activation-related pseudoallergy: a stress reaction in blood triggered by nanomedicines and biologicals. Mol Immunol 2014;61:163-73.
9. Szebeni J, Jiskoot W. Immunological issues with nanomedicines: immunogenicity, hypersensitivity, accelerated clearance and immune suppression. In: Torchillin V, editor. Handbook of nanobiomedical research. Singapore: World Scientific, 2014:45-73.
10. Szebeni J. Complement activation by nanomaterials. In: Fadeel B, editor. Handbook of safety assessment of nanomaterials: from toxicological testing to personalized medicine. Pan Stanford Publishing Pte. Ltd., 2015:281-310.
11. Meth MJ, Maibach HI. Current understanding of contrast media reactions and implications for clinical management. Drug Saf 2006;29:133-41.
12. Kovoor ET, Morgan G. Severe transient leukopenia following hysterosalpingography. Gynecol Obstet Invest 2010;69:190-2.
13. Szebeni J, Fontana JL, Wassef NM, Mongan PD, Morse DS, Dobbins DE, et al. Hemodynamic changes induced by liposomes and liposome-encapsulated hemoglobin in pigs: a model for pseudoallergic cardiopulmonary reactions to liposomes. Role of complement and inhibition by soluble CR1 and anti-C5a antibody. Circulation 1999;99:2302-9.
14. Hugli TE. The structural basis for anaphylatoxin and chemotactic functions of C3a, C4a, and C5a. Crit Rev Immunol 1981;1:321-66.
15. Hugli TE, Marceau F. Effects of the C5a anaphylatoxin and its relationship to cyclo-oxygenase metabolites in rabbit vascular strips. Br J Pharmacol 1985;84:725-33.
16. Ember JA, Sanderson SD, Hugli TE, Morgan EL. Induction of interleukin- 8 synthesis from monocytes by human C5a anaphylatoxin. Am J Pathol 1994;144:393-403.
17. Rabinovici R, Rudolph AS, Feuerstein G. Characterization of hemodynamic, hematologic and biochemical responses to administration of liposome-encapsulated hemoglobin in the conscious, freely moving rat. Circ Shock 1989;29:115-32.
18. Rabinovici R, Rudolph AS, Ligler FS, Smith III EF, Feuerstein G. Biological responses to exchange transfusion with liposomeencapsulated hemoglobin. Circ Shock 1992;37:124-33.
19. Rabinovici R, Rudolph AS, Vernick J, Feuerstein G. Lyophilized liposome-encapsulated hemoglobin: evaluation of hemodynamic, biochemical, and hematologic responses. Crit Care Med 1994;22:480-5.
20. Dézsi L, Fülöp T, Mészáros T, Szénási G, Urbanics R, Vázsonyi C, et al. Features of complement activation-related pseudoallergy to liposomes with different surface charge and PEGylation: comparison of the porcine and rat responses. J Control Release 2014;195:2-10.
21. Phillips WT, Klipper R, Fresne D, Rudolph AS, Javors M, Goins B. Platelet reactivity with liposome-encapsulated hemoglobin in the rat. Exp Hematol 1997;25:1347-56.
22. Klos A, Tenner AJ, Johswich KO, Ager RR, Reis ES, Köhl J. The role of the anaphylatoxins in health and disease. Mol Immunol 2009;46:2753-66.
23. Klos A, Wende E, Wareham KJ, Monk PN. International union of pharmacology. LXXXVII. complement peptide C5a, C4a, and C3a receptors. Pharmacol Rev 2013;65:500-43.
24. Heideman M, Hugli TE. Anaphylatoxin generation in multisystem organ failure. J Trauma 1984;24:1038-43.
25. Hugli TE. Structure and function of anaphylatoxins. Spring Semin Immunopathol 1984;7:193-219.
26. Marceau F, Lundberg C, Hugli TE. Effects of anaphylatoxins on circulation. Immunopharmacol 1987;14:67-84.
27. Mousli M, Hugli TE, Landry Y, Bronner C. A mechanism of action for anaphylatoxin C3a stimulation of mast cells. J Immunol 1992;148:2456-61.
28. Yancey KB, Lawley TJ, Dersookian M, Harvath L. Analysis of the interaction of human C5a and C5a des Arg with human monocytes and neutrophils: flow cytometric and chemotaxis studies. J Invest Dermatol 1989;92:184-9.
29. Stahl GL, Behroozi F, Morrissey M. Monoclonal antibody, GS1, functionally inhibits porcine C5a induced neutrophil activation, but not C5b-9 formation. FASEB J 1997;11:A331.
30. Goins B, Phillips WT, Klipper R, Rudolph AS. Role of complement in rats injected with liposome-encapsulated hemoglobin. J Surg Res 1997;68:99-105.
31. Nityanand S, Pande I, Bajpai VK, Singh L, Chandra M, Singh BN. Platelets in essential hypertension. Thrombosis Res 1993;72:447-54.
32. Nadar SK, Blann AD, Lip GY. Plasma and platelet-derived vascular endothelial growth factor and angiopoietin-1 in hypertension: effects of antihypertensive therapy. J Intern Med 2004;256:331-7.
33. Nadar SK, Blann AD, Kamath S, Beevers DG, Lip GY. Platelet indexes in relation to target organ damage in high-risk hypertensive patients: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). J Am Coll Cardiol 2004;44:415-22.
34. Broijersen A, Hamsten A, Eriksson M, Angelin B, Hjemdahl P. Platelet activity in vivo in hyperlipoproteinemia-importance of combined hyperlipidemia. Thromb Haemost 1998;79:268-75.
35. Tian J, Zhu T, Liu J, Guo Z, Cao X. Platelets promote allergic asthma through the expression of CD154. Cell Mol Immunol 2014 Nov 24. doi: 10.1038/cmi.2014.111. [Epub ahead of print].
36. Cattaneo M. The platelet P2 receptors in inflammation. Hamostaseologie 2015;35(2). Epub 2015/01/13.
37. Jinchuan Y, Zonggui W, Jinming C, Li L, Xiantao K. Upregulation of CD40-CD40 ligand system in patients with diabetes mellitus. Clin Chim Acta 2004;339:85-90.
38. Lupu C, Manduteanu I, Calb M, Simionescu N, Simionescu M, Ionescu M. Some major plasmalemma proteins of human diabetic platelets are involved in the enhanced platelet adhesion to cultured valvular endothelial cells. Platelets 1993;4:79-84.
39. Nadar SK, Lip GY, Blann AD. Platelet morphology, soluble P selectin and platelet P-selectin in acute ischaemic stroke. The West Birmingham stroke project. Thromb Haemost 2004;92:1342-8.
40. Patzelt J, Mueller KA, Breuning S, Karathanos A, Schleicher R, Seizer P, et al. Expression of anaphylatoxin receptors on platelets in patients with coronary heart disease. Atherosclerosis 2015;238:289-95.
41. Peerschke EI, Yin W, Grigg SE, Ghebrehiwet B. Blood platelets activate the classical pathway of human complement. J Thromb Haemost 2006;4:2035-42.
42. Peerschke EI, Yin W, Ghebrehiwet B. Platelet mediated complement activation. Adv Exp Med Biol 2008;632:81-91.
43. Yin W, Ghebrehiwet B, Peerschke EI. Expression of complement components and inhibitors on platelet microparticles. Platelets 2008;19:225-33.
44. Peerschke EI, Yin W, Ghebrehiwet B. Complement activation on platelets: implications for vascular inflammation and thrombosis. Mol Immunol 2010;47:2170-5.
45. Peerschke EI, Andemariam B, Yin W, Bussel JB. Complement activation on platelets correlates with a decrease in circulating immature platelets in patients with immune thrombocytopenic purpura. Br J Haematol 2010;148:638-45.
46. Del Conde I, Cruz MA, Zhang H, Lopez JA, Afshar-Kharghan V. Platelet activation leads to activation and propagation of the complement system. J Exp Med 2005;201:871-9.
47. Peerschke EI, Murphy TK, Ghebrehiwet B. Activation-dependent surface expression of gC1qR/p33 on human blood platelets. Thromb Haemost 2003;89:331-9.
48. Hamad OA, Nilsson PH, Lasaosa M, Ricklin D, Lambris JD, Nilsson B, et al. Contribution of chondroitin sulfate A to the binding of complement proteins to activated platelets. PLoS One 2010;5:e12889.
49. Kishimoto TK, Viswanathan K, Ganguly T, Elankumaran S, Smith S, Pelzer K, et al. Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl J Med 2008;358:2457-67.
50. Fukuoka Y, Hugli TE. Demonstration of a specific C3a receptor on guinea pig platelets. J Immunol 1988;140:3496-501.
51. Wiedmer T, Sims PJ. Effect of complement proteins C5b-9 on blood platelets. Evidence for reversible depolarization of membrane potential. J Biol Chem 1985;260:8014-9.
52. Ando B, Wiedmer T, Hamilton KK, Sims PJ. Complement proteins C5b-9 initiate secretion of platelet storage granules without increased binding of fibrinogen or von Willebrand factor to newly expressed cell surface GPIIb-IIIa. J Biol Chem 1988;263:11907-14.
53. Wiedmer T, Esmon CT, Sims PJ. Complement proteins C5b-9 stimulate procoagulant activity through platelet prothrombinase. Blood 1986;68:875-80.
54. Wiedmer T, Esmon CT, Sims PJ. On the mechanism by which complement proteins C5b-9 increase platelet prothrombinase activity. J Biol Chem 1986;261:14587-92.
55. Polley MJ, Nachman RL. Human platelet activation by C3a and C3a des-Arg. J Exp Med 1983;158:603-15.
56. Sinauridze EI, Kireev DA, Popenko NY, Pichugin AV, Panteleev MA, Krymskaya OV, et al. Platelet microparticle membranes have 50- to 100-fold higher specific procoagulant activity than activated platelets. Thromb Haemost 2007;97:425-34.
57. George JN, Pickett EB, Saucerman S, McEver RP, Kunicki TJ, Kieffer N, et al. Platelet surface glycoproteins. Studies on resting and activated platelets and platelet membrane microparticles in normal subjects, and observations in patients during adult respiratory distress syndrome and cardiac surgery. J Clin Invest 1986;78:340-8.
58. Martinez MC, Tesse A, Zobairi F, Andriantsitohaina R. Shed membrane microparticles from circulating and vascular cells in regulating vascular function. Am J Physiol Heart Circ Physiol 2005;288:H1004-9.
59. Barry OP, Pratico D, Savani RC, FitzGerald GA. Modulation of monocyte-endothelial cell interactions by platelet microparticles. J Clin Invest 1998;102:136-44.
60. Miajlovic H, Loughman A, Brennan M, Cox D, Foster TJ. Both complement- and fibrinogen-dependent mechanisms contribute to platelet aggregation mediated by Staphylococcus aureus clumping factor B. Infect Immun 2007;75:3335-43.
61. Sims PJ, Rollins SA, Wiedmer T. Regulatory control of complement on blood platelets. Modulation of platelet procoagulant responses by a membrane inhibitor of the C5b-9 complex. J Biol Chem 1989;264:19228-35.
62. Mevorach D, Mascarenhas JO, Gershov D, Elkon KB. Complement- dependent clearance of apoptotic cells by human macrophages. J Exp Med 1998;188:2313-20.
63. Speidl WS, Exner M, Amighi J, Kastl SP, Zorn G, Maurer G, et al. Complement component C5a predicts future cardiovascular events in patients with advanced atherosclerosis. Eur Heart J 2005;26:2294-9.
64. Movat HZ, Uriuhara T, Taichman NS, Rowsell HC, Mustard JF. The role of PMN-leucocyte lysosomes in tissue injury, inflammation and hypersensitivity. VI. The participation of the PMN-leucocyte and the blood platelet in systemic aggregate anaphylaxis. Immunology 1968;14:637-48.
65. Fiane AE, Videm V, Johansen HT, Mellbye OJ, Nielsen EW, Mollnes TE. C1-inhibitor attenuates hyperacute rejection and inhibits complement, leukocyte and platelet activation in an ex vivo pig-tohuman perfusion model. Immunopharmacology 1999;42:231-43.
66. Seifert PS, Hansson GK. Complement receptors and regulatory proteins in human atherosclerotic lesions. Arteriosclerosis 1989;9:802-11.
67. Weiser MR, Williams JP, Moore FD, Jr., Kobzik L, Ma M, Hechtman HB, et al. Reperfusion injury of ischemic skeletal muscle is mediated by natural antibody and complement. J Exp Med 1996;183:2343-8.